Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The systemic and local immunosuppression exhibited by pancreatic ductal adenocarcinoma (PDAC) contributes significantly to its aggressive nature. There is a need for a greater understanding of the mechanisms behind this profound immune evasion, which makes it one of the most challenging malignancies to treat and thus one of the leading causes of cancer death worldwide. The gut microbiome is now thought to be the largest immune organ in the body and has been shown to play an important role in multiple immune-mediated diseases. By summarizing the current literature, this review examines the mechanisms by which the gut microbiome may modulate the immune response to PDAC. Evidence suggests that the gut microbiome can alter immune cell populations both in the peripheral blood and within the tumour itself in PDAC patients. In addition, evidence suggests that the gut microbiome influences the composition of the PDAC tumour microbiome, which exerts a local effect on PDAC tumour immune infiltration. Put together, this promotes the gut microbiome as a promising route for future therapies to improve immune responses in PDAC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930865 | PMC |
| http://dx.doi.org/10.3390/cancers16050996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.
Front Immunol
September 2025
Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Cancer is a multifaceted disease driven by a complex interplay of genetic predisposition, environmental factors and lifestyle habits. With the accelerating pace of cancer research, the gut microbiome has emerged as a critical modulator of human health and immunity. Disruption in the gut microbial populations and diversity, known as dysbiosis, has been linked with the development of chronic inflammation, oncogenesis, angiogenesis and metastasis.
View Article and Find Full Text PDFGut microbiota dysbiosis in people living with HIV who have cancer: novel insights and diagnostic potential.
Front Immunol
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Background: People living with HIV(PLWH) are a high-risk population for cancer. We conducted a pioneering study on the gut microbiota of PLWH with various types of cancer, revealing key microbiota.
Methods: We collected stool samples from 54 PLWH who have cancer (PLWH-C), including Kaposi's sarcoma (KS, n=7), lymphoma (L, n=22), lung cancer (LC, n=12), and colorectal cancer (CRC, n=13), 55 PLWH who do not have cancer (PLWH-NC), and 49 people living without HIV (Ctrl).
Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?
Front Immunol
September 2025
Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
In the last decades, immunotherapy has revolutionized cancer treatment. Despite its success, a significant number of patients fail to respond, and the underlying causes of ineffectiveness remain poorly understood. Factors such as nutritional status and body composition are emerging as key predictors of immunotherapy outcomes.
View Article and Find Full Text PDFThe Role of Plasma Metabolites in Mediating the Effect of Gut Microbiota on Obstructive Sleep Apnea: A Two-Step, Two-Sample Mendelian Randomization Study.
Nat Sci Sleep
September 2025
Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Background: Recent research has increasingly underscored a significant correlation between gut microbiota and obstructive sleep apnea (OSA). Probiotics have emerged as promising adjunctive interventions for OSA. Metabolites and their related biochemical pathways have emerged as important contributors to the development of OSA.
View Article and Find Full Text PDFUsing molecular methods to diagnose, classify, and treat neonatal sepsis: a scoping review.
Front Pediatr
August 2025
Department of Neonatal Research, Inova Health Services, Falls Church, VA, United States.
Introduction: Neonatal sepsis is a dysregulated immune response to bloodstream infection causing serious disease and death. Our review seeks to integrate the knowledge gained from studies of multiple molecular methods- such as genomics, metabolomics, transcriptomics, and the gut microbiome- in the setting of neonatal sepsis that may improve the diagnosis, classification, and treatment of the disease. Sepsis claims over 200,000 lives annually worldwide and remains a top 10 cause of infant mortality in the US.
View Article and Find Full Text PDF